Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astrocyte cell therapy - Kadimastem

Next Previous
Drug Profile

Astrocyte cell therapy - Kadimastem

Alternative Names: AstroRx

Latest Information Update: 14 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kadimastem
  • Class Pluripotent stem cell therapies; Stem cell therapies
  • Mechanism of Action Glial cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Amyotrophic lateral sclerosis

Most Recent Events

  • 14 Jun 2023 Kadimastem clears an IND application with the with the US FDA in USA for commencing a phase IIa clinical trial in Amyotrophic lateral sclerosis (Kadimastem pipeline June 2023)
  • 28 Feb 2023 Kadimastem files an IND application with the US FDA in USA for commencing a phase IIa clinical trial in Amyotrophic lateral sclerosis (Kadimastem pipeline June 2023)
  • 09 Aug 2022 Kadimastem plans to file an IND application with the US FDA for Amyotrophic lateral sclerosis (original and frozen version of the cell therapy product) in 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top